Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.77 |
| ▸ | DHODH | Q02127 | 6/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | EIF4A1 | P60842 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8613758 | 0.87 | MAPT (1.00) | MAPTALDH1A1DHODHSMN1; SMN2KDM4E | |
| SCHEMBL1899228 | 0.86 | EIF4A1 (0.73) | MAPTALDH1A1DHODHSMN1; SMN2KDM4E | |
| SCHEMBL1898782 | 0.86 | MAPT (0.77) | MAPTALDH1A1DHODHSMN1; SMN2KDM4E | |
| SCHEMBL29536364 | 0.84 | DHODH (1.00) | DHODHSMN1; SMN2KDM4ELMNAPDE10A | |
| SCHEMBL2467110 | 0.84 | DHODH (1.00) | DHODHSMN1; SMN2KDM4ELMNAPDE10A | |
| Cinchophen SCHEMBL7588217 | 0.84 | KDM4E (1.00) | ALDH1A1DHODHSMN1; SMN2KDM4ELMNA | |
| Cinchophen SCHEMBL25519 | 0.84 | KDM4E (1.00) | ALDH1A1DHODHSMN1; SMN2KDM4ELMNA | |
| Cinchophen SCHEMBL29376617 | 0.84 | KDM4E (1.00) | ALDH1A1DHODHSMN1; SMN2KDM4ELMNA | |
| SCHEMBL10608949 | 0.83 | MAPT (0.69) | MAPTALDH1A1SMN1; SMN2KDM4ELMNA | |
| Cinchophen SCHEMBL4464779 | 0.82 | KDM4E (0.97) | ALDH1A1DHODHSMN1; SMN2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2325181-B1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2017-03-29 | — | — | EP | disclosed |
| CN-102099352-B | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient | PHARMA IP GENERAL INC ASS | 2014-02-26 | — | — | CN | disclosed |
| US-8466290-B2 | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient | PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) | 2013-06-18 | — | — | US | disclosed |
| US-20110172429-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | PHARMA IP GENERAL INCORPORATED ASSOCIATION (JP) | 2011-07-14 | — | — | US | disclosed |
| CN-102099352-A | STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient | PHARMA IP GENERAL INC ASS | 2011-06-15 | — | — | CN | disclosed |
| EP-2325181-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | Pharma Ip General Incorporated Association (JP) | 2011-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172429-A1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | STAT3, STAT4, STAT5B | MAPT 4208/4885ALDH1A1 3308/4885DHODH 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.